90566-23-7

Upstream product

• 1377582-41-6 4-isopropoxy-3-nitro-benzenesulfonamide 
• 1493-27-2 ortho-nitrofluorobenzene 
• 406233-31-6 4-fluoro-3-nitrobenzenesulfonamide 

Downstream Products

• 1377582-43-8 4-isopropoxy-3-thioureido-benzenesulfonamide 
• 1415135-67-9 4-isopropoxy-3-((4-(4-(1,2,3,6-tetrahydropyridin-4-yl)phenyl)thiazol-2-yl)amino)benzenesulfonamide 
• 1415135-19-1 3-((4-(4-bromophenyl)thiazol-2-yl)amino)-4-isopropoxybenzenesulfonamide 
• 1377963-23-9 tert-butyl 4-(5-(2-((2-isopropoxy-5-sulfamoylphenyl)amino)thiazol-4-yl)pyridin-2-yl)piperidine-1-carboxylate 
• 1377963-20-6 tert-butyl 5-(2-((2-isopropoxy-5-sulfamoylphenyl)amino)thiazol-4-yl)-5',6'-dihydro-[2,4'-bipyridine]-1'(2'H)-carboxylate 
• 1378023-06-3 3-((4-(2-(hydroxymethyl)-1-methyl-1H-benzo[d]imidazol-5-yl)thiazol-2-yl)amino)-4-isopropoxybenzenesulfonamide 

Relevant academic research and scientific papers

BIS HETEROARYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to thiazole I and its therapeutic and prophylactic uses, wherein the variables A, Q, J, R1, R3, and R5 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

FUSED HETEROARYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to thiazole I and its therapeutic and prophylactic uses, wherein the variables A, Q, J, R1, R3, and R5 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

PYRIDYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to thiazole I and its therapeutic and prophylactic uses, wherein the variables Rz, Q, J, R1, R3, R5, and R6 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

BISTHIAZOLE INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to bisthiazole I and its therapeutic and prophylactic uses, wherein the variables A, R5, R6, and R7 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to tricycle I and its therapeutic and prophylactic uses, wherein the variables C1, C2, Z1, Z2, Q, J, R1, and R3 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

PHENYL-THIAZOLYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

This invention relates to phenyl thiazole I and its therapeutic and prophylactic uses, wherein the variables Rz, Q, J, R1, R3, R5, R6, and R7 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.